...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Outcomes of percutaneous interventions in transposed hemodialysis fistulas compared with nontransposed fistulas and grafts
【24h】

Outcomes of percutaneous interventions in transposed hemodialysis fistulas compared with nontransposed fistulas and grafts

机译:与未转位瘘管和移植物相比,经转位血液透析瘘管经皮介入治疗的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To compare postpercutaneous intervention outcomes of autogenous venous-transposition arteriovenous fistulas (AVFs) versus those of autogenous nontransposed AVFs (nAVFs) and prosthetic arteriovenous grafts (AVGs). Materials and Methods A total of 591 hemodialysis accesses (195 transposed AVFs [tAVFs], 205 nAVFs, 191 AVGs) in 522 patients (278 male; mean age, 57 y; range, 15-91 y) underwent percutaneous transluminal angioplasty (PTA) and/or mechanical thrombectomy (ie, declotting). Access characteristics, surgical history, percutaneous interventions, postinterventional primary and secondary access patency, and follow-up data were collected. Cox proportional-hazards regression analyses, Fisher exact tests, and χ2 tests were performed. Results Mean follow-up period was 32 months. Mean access ages at initial percutaneous intervention were 260 days (tAVF), 206 days (nAVF), and 176 days (AVG; P .01). One-year postinterventional primary patency (PIPP) rates were 25% (tAVF), 24% (nAVF), and 14% (AVG). One-year postinterventional secondary patency (PISP) rates were 77% (tAVF), 61% (nAVF), and 63% (AVG). Median PIPP durations were 138 days (tAVF), 121 days (nAVF), and 79 days (AVG; P =.0001). Median PISP durations were 1,076 days (tAVF), 783 days (nAVF), and 750 days (AVG; P =.019). Total interventions needed to maintain PISP were 2.4 (tAVF), 1.3 (nAVF), and 3.2 (AVG) per patient-year (P .001), which included 1.9, 1.2, and 1.4 PTAs (P .01) and 0.45, 0.15, and 1.8 declotting procedures, respectively (P .001). Conclusions Based on the number of percutaneous interventions needed to maintain PISP, these results confirm the current Dialysis Outcomes Quality Initiative access preference of nAVFs before tAVFs before AVGs. tAVFs offered superior postinterventional outcomes than AVGs. With additional interventions, tAVFs could even outperform nAVFs in terms of PISP.
机译:目的比较自体静脉转位动静脉瘘(AVF)与自体非转位AVF(nAVF)和人工动静脉移植物(AVG)的经皮介入治疗效果。材料和方法在522例患者中(共278位男性;平均年龄57岁;范围15-91岁),共进行了591次血液透析通路(195例换位AVF [tAVF],205例nAVF,191例AVG),进行了经皮腔内血管成形术(PTA)和/或机械血栓切除术(即去凝血)。收集访问特征,手术史,经皮干预,介入后一级和二级介入通畅性以及随访数据。进行了Cox比例风险回归分析,Fisher精确检验和χ2检验。结果平均随访期为32个月。初始经皮介入治疗的平均进入年龄为260天(tAVF),206天(nAVF)和176天(AVG; P <.01)。一年的介入后初级通畅率(PIPP)为25%(tAVF),24%(nAVF)和14%(AVG)。一年的干预后二次通畅(PISP)率为77%(tAVF),61%(nAVF)和63%(AVG)。 PIPP持续时间的中位数为138天(tAVF),121天(nAVF)和79天(AVG; P = .0001)。 PISP中位数持续时间为1,076天(tAVF),783天(nAVF)和750天(AVG; P = .019)。维持PISP所需的总干预量为每患者年2.4(tAVF),1.3(nAVF)和3.2(AVG)(P <.001),其中包括1.9、1.2和1.4 PTA(P <.01)和0.45 ,分别为0.15和1.8的凝血过程(P <.001)。结论基于维持PISP所需的经皮干预措施的数量,这些结果证实了当前的tAVF之前,AVG之前,nAVF的透析结果质量倡议获得偏好。与AVG相比,tAVF的介入后效果更好。通过额外的干预,就PISP而言,tAVF甚至可以胜过nAVF。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号